Activities Report and Appendix 4C for December 2021 Quarter
Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December...
Read moreLatest News
Category: News
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or...
Read more
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder...
Read more
TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021
Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab)...
Read more
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product,...
Read more
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging...
Read more
First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea
With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in...
Read more
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art...
Read more
ZIRCON Presentation at International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron...
Read more